Scalp health is essential for hair growth and overall hair vitality. Regular cleansing, moisturising, and protecting from ...
Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...
Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...
SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
The lack of awareness about rare diseases like prurigo nodularis and available treatment options is anticipated to impede market growth.
Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...
Lal ultimately prescribed Beckham with Zoryve, an FDA-approved steroid-free topical foam to treat seborrheic dermatitis, ...
Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. | Arcutis ...
As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.
Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback